Search Results for: NorthStar Medical

Wisconsin Roundup: Exact Sciences, Promega, WARF, & More

Here are some of the past week’s major headlines from Wisconsin’s tech and innovation community: —The new board of directors at Fitchburg-based life sciences supplier Promega has rejected a hostile takeover attempt, the Wisconsin State Journal reported. Two shareholders—Ted Kellner, executive chairman of Milwaukee-based Fiduciary Management, and Nathan Brand, a Miami real estate developer with … Continue reading “Wisconsin Roundup: Exact Sciences, Promega, WARF, & More”

Wisconsin Roundup: Johnson Controls, BrightStar, Orbitec, & More

Here are some of the past week’s major headlines from Wisconsin’s tech and innovation community: —The BrightStar Wisconsin Foundation announced investments in five companies around the state. It invested $250,000 in MCT of Wisconsin, $150,000 apiece in Dock Technologies and Okanjo, and $50,000 apiece in AltusMedical Group and GrocerKey. BrightStar has made investments in 22 … Continue reading “Wisconsin Roundup: Johnson Controls, BrightStar, Orbitec, & More”

Bluebird, Regulators Map Out Approval Plan For Gene Therapy

One of gene therapy’s major unanswered questions is just what it’ll take to convince U.S. regulators to approve one of these treatments. With a gene therapy that’s already produced promising results in a few patients in clinical trials, Bluebird Bio has a chance to pave the way. And today it’s cut a deal with the … Continue reading “Bluebird, Regulators Map Out Approval Plan For Gene Therapy”

Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study

As a gene therapy company, Bluebird Bio was a surprising IPO star in 2013. After all, it’s working in a field that was kicked to the curb in the previous decade. What’s more, it made its IPO pitch on the back of the slimmest amount of data. But details from a new study released this … Continue reading “Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study”

Rock Health Honors “Top 50” Digital Health Entrepreneurs

Who are the entrepreneurs pushing hardest for technology advances that will connect patients with better healthcare? They’re people like Sean Duffy, who’s using the Web to help people make behavioral changes that could head off Type 2 diabetes at his startup Omada Health, and Joanne Rohde, whose company Axial Exchange is building systems that help … Continue reading “Rock Health Honors “Top 50” Digital Health Entrepreneurs”

A Brief Year-End Review of Seattle Biotech

Well, 2009 did not turn out to be the biotechnology disaster here in Seattle that many people had predicted. By my reckoning, only four of the local biotech companies that I track on my website went bust in 2009 (Eden Biosciences, VizX Labs, Northstar Neurosciences, and Rosetta Inpharmatics). This last blow was softened when Microsoft … Continue reading “A Brief Year-End Review of Seattle Biotech”

The Northwest Biotech Survival Index 2: Companies Scraping By in Downturn

When I last crunched the financial numbers of the Northwest’s life sciences companies in November, the local contingent was taking a beating, and it has only continued. Just three of the 12 publicly-traded life sciences companies in the Northwest—Seattle Genetics, SonoSite, and Dendreon—were really well-positioned to weather this downturn with more than $100 million in … Continue reading “The Northwest Biotech Survival Index 2: Companies Scraping By in Downturn”

Amgen Tries to “Personalize” Drug, VLST Snags Deal, Tobacco Money Backs Research, & More Seattle-Area Life Sciences News

Many life sciences shut down operations between Christmas and New Year’s Day, so obviously they need to cram a lot of work into weeks like the last one. Here’s a rundown of the big news. —Amgen, the giant biotech with about 1,000 employees in Washington, went before an FDA advisory panel to make an unusual … Continue reading “Amgen Tries to “Personalize” Drug, VLST Snags Deal, Tobacco Money Backs Research, & More Seattle-Area Life Sciences News”

Biotech Survival Index: Cash Running Low at Seattle Life Sciences Companies

Two questions matter most to the financial survival of a biotech company: How much cash does it have in the bank, and how fast is it burning through it? That’s especially true in dark economic days, so I checked on just how well-prepared Seattle’s public biotech companies are to weather this particular storm. The findings … Continue reading “Biotech Survival Index: Cash Running Low at Seattle Life Sciences Companies”

Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News

Last week brought another mixed bag of news from Seattle biotech. —Tysabri. The most effective drug on the market for multiple sclerosis isn’t sold by a Seattle biotech company, but it has its origins in a lab here at the Fred Hutchinson Cancer Research Center. —ZymoGenetics had yet another good news/bad news week. The Seattle … Continue reading “Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News”

NeuroVista, Emerging from Stealth Mode, Unveils Technology to Predict Epileptic Seizures

[Updated and corrected: 1 pm Pacific 9/9/10] NeuroVista has said next to nothing in public about how its technology works, until today. After sitting down for an exclusive interview with CEO John Harris at his office in Seattle’s Fisher Plaza, all I can say is that if its technology is half as good as he … Continue reading “NeuroVista, Emerging from Stealth Mode, Unveils Technology to Predict Epileptic Seizures”